Mustang Bio Inc.

1.35
-0.09 (-6.25%)
At close: Apr 03, 2025, 3:59 PM

Company Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.

Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.

The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus.

It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH.

The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Mustang Bio Inc.
Mustang Bio Inc. logo
Country United States
IPO Date Aug 22, 2017
Industry Biotechnology
Sector Healthcare
Employees 80
CEO Dr. Manuel Litchman M.D.

Contact Details

Address:
377 Plantation Street
Worcester, Massachusetts
United States
Website https://www.mustangbio.com

Stock Details

Ticker Symbol MBIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001680048
CUSIP Number 62818Q104
ISIN Number US62818Q2030
Employer ID 47-3828760
SIC Code 2834

Key Executives

Name Position
Dr. Manuel Litchman M.D. President, Chief Executive Officer, Interim Chief Financial Officer & Director
Greg Furrow M.S. Chief Quality Officer
Michael S. Weiss Esq. Executive Chairman
Peter Carney Controller & Interim Chief Accounting Officer
Robyn M. Hunter Corporate Secretary

Latest SEC Filings

Date Type Title
Apr 02, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 02, 2025 4 Filing
Apr 01, 2025 POS EX Filing
Apr 01, 2025 424B3 Filing
Mar 28, 2025 10-K Annual Report
Mar 05, 2025 8-K Current Report
Mar 03, 2025 DEF 14C Filing
Feb 27, 2025 424B3 Filing
Feb 27, 2025 8-K Current Report
Feb 21, 2025 PRE 14C Filing